Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958092 | 1.00 | KDM4E (0.58) | KDM4EHSD17B10MGLLTDP1MAOB | |
| SCHEMBL13457620 | 0.78 | KDM4E (0.60) | KDM4EHSD17B10MGLLTDP1MAOB | |
| SCHEMBL155365 | 0.77 | KDM4E (0.58) | KDM4EHSD17B10MGLLTDP1GPR35 | |
| SCHEMBL2861393 | 0.77 | TDP1 (0.58) | KDM4EHSD17B10MGLLTDP1CYP1A2 | |
| SCHEMBL31416604 | 0.77 | KDM4E (0.58) | KDM4EHSD17B10MGLLTDP1GPR35 | |
| SCHEMBL7309893 | 0.77 | KDM4E (0.58) | KDM4EHSD17B10MGLLTDP1MAOB | |
| SCHEMBL147973 | 0.74 | KDM4E (1.00) | KDM4EHSD17B10MGLLTDP1MAOB | |
| SCHEMBL15031529 | 0.74 | MAOB (0.55) | KDM4EHSD17B10MAOBGPR35ALDH1A1 | |
| SCHEMBL746805 | 0.73 | KDM4E (0.53) | KDM4EHSD17B10MGLLTDP1GPR35 | |
| SCHEMBL13048738 | 0.73 | KDM4E (0.53) | KDM4EHSD17B10MGLLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024061371-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 广州威诺森医药科技有限公司 | 2024-03-28 | — | — | WO | disclosed |
| EP-2661431-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2681207-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2016-12-28 | — | — | EP | disclosed |
| CN-103459382-B | For suppressing the heterocyclic compound of PASK | 拜奥埃内杰尼克斯公司 | 2016-06-29 | — | — | CN | disclosed |
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-9073902-B2 | Substituted quinoxaline carboxylic acid compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-8916561-B2 | Substituted quinoxaline compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-23 | — | — | US | disclosed |
| US-8912188-B2 | Substituted quinoxaline carboxylic acids for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| US-20020037885-A1 | Therapeutic compounds | DIJCKS FREDERICUS ANTONIUS (NL) | 2002-03-28 | — | — | US | disclosed |
| US-6313139-B1 | ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS | AKZO NOBEL N. V. (NL) | 2001-11-06 | — | — | US | disclosed |
| EP-1035843-A2 | I h?-MODULATORS | Akzo Nobel N.V. (NL) | 2000-09-20 | — | — | EP | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| WO-1999032482-A1 | HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1999018941-A2 | Ih-MODULATORS | AKZO NOBEL N.V. (NL) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | KDM4E 1112/4885HSD17B10 80/4885MGLL 1205/4885 |
| US-20020037885-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | KDM4E 1272/4885HSD17B10 1523/4885MGLL 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.